TIL therapy is the most personalized treatment; therefore, the specific TILs product must be prepared for each patient.1067 Several strategies have been developed to overcome this issue, such as CD8+ enriched young TILs,1068 rapid expansion by anti-CD3 antibody, IL-2 and feeder cells,1069 generating artificial APCs for TIL expansion,1070 and incorporation of costimulatory signals.1071 Additionally, combination of TILs with other anti-tumor therapies are also developed and tested in clinical and preclinical studies.1072. The gene discussed is CD8A; the disease is neoplasm.